Ifekthri Inikeza ngokuqondile i-4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2

Ngokuvamile sicabanga futhi sizilolonge okuhambisana nokushintsha kwesimo sakho, futhi sikhule.Sihlose ukuzuza ingqondo nomzimba ocebile kanye nokuphila kwefekthri Ukuhlinzeka ngokuqondile nge-4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2, Inhloso yethu kungaba ukusiza amakhasimende azi izinhloso zawo. .Besilokhu sikhiqiza imizamo emihle yokufeza lesi simo esibucayi futhi sikwamukela ngobuqotho ukuze nakanjani usibhalisele.
Ngokuvamile sicabanga futhi sizilolonge okuhambisana nokushintsha kwesimo sakho, futhi sikhule.Sihlose ukuzuza ingqondo nomzimba ocebile kanye nokuphilaI-China 4-Dibuthylamino-2-Hydroxybenzophenone ne-Bba, Ukutholakala kwethu okuqhubekayo kwemikhiqizo yezinga eliphezulu nezisombululo kuhlanganiswe nesevisi yethu enhle kakhulu yokuthengisa ngaphambi kokuthengisa nangemva kokuthengisa kuqinisekisa ukuncintisana okuqinile emakethe eyandayo yomhlaba wonke.wamukelekile amakhasimende amasha namadala avela kuyo yonke imikhakha yempilo ukuze asithinte ukuze uthole ubudlelwano bebhizinisi besikhathi esizayo kanye nempumelelo efanayo!

I-2′-Methoxy-3'-nitro-biphenyl-3-carboxylic acid isetshenziswa njengendawo emaphakathi ye-Eltrombopag.
I-Eltrombopag, eyakhiwe yi-GlaxoSmithKline (GSK) e-UK futhi kamuva yathuthukiswa ngokuhlanganyela ne-Novartis e-Switzerland, ingeyokuqala futhi iwukuphela kwe-molecule encane egunyazwe i-non-peptide TPO receptor agonist emhlabeni.I-Eltrombopag yagunyazwa yi-FDA yase-US ngo-2008 yokwelapha i-idiopathic thrombocytopenic purpura (ITP), nango-2014 ukuze kwelashwe i-aplastic anemia enzima (AA).Futhi isidakamizwa sokuqala esigunyazwe yi-US FDA sokwelapha i-AA eminyakeni engama-30 yakamuva.
Ngo-December 2012, i-US FDA yagunyaza i-Elthrombopag yokwelapha i-thrombocytopenia ezigulini ezine-hepatitis C (CHC) engapheli, ukuze iziguli ze-hepatitis C ezinokubikezelwa okungekuhle ngenxa yokubala kweplatelet ephansi zikwazi ukuqala futhi zilondoloze ukwelashwa okujwayelekile okusekelwe kwe-interferon kwezifo zesibindi.NgoFebhuwari3, 2014, i-GlaxoSmithKline yamemezela ukuthi i-FDA inikeze ukuphumelela komuthi wokwelapha i-Eltrombopag wokwelapha i-hemopenia ezigulini ezine-chemicalbook aplastic anemia (SAA) enzima kakhulu engazange iphendule ngokugcwele ku-immunotherapy.Ngomhla zingama-24 ku-Agasti, i-2015, i-US FDA igunyaze i-Eltrombopag yokwelashwa kwe-thrombocytopenia kubantu abadala kanye nezingane ezineminyaka engu-1 nangaphezulu ezine-immune immune thrombocytopenia (ITP) ezingenampendulo eyanele ku-corticosteroids, i-immunoglobulins noma i-splenectomy.NgoJanuwari4, 2018, i-Eltrombopag yagunyazwa ukuthi ifakwe ohlwini e-China ukuze zelashwe i-immune immune thrombocytopenia (ITP).

Ngokuvamile sicabanga futhi sizilolonge okuhambisana nokushintsha kwesimo sakho, futhi sikhule.Sihlose ukuzuza ingqondo nomzimba ocebile kanye nokuphila kwefekthri Ukuhlinzeka ngokuqondile nge-4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2, Inhloso yethu kungaba ukusiza amakhasimende azi izinhloso zawo. .Besilokhu sikhiqiza imizamo emihle yokufeza lesi simo esibucayi futhi sikwamukela ngobuqotho ukuze nakanjani usibhalisele.
Factory Direct supplyI-China 4-Dibuthylamino-2-Hydroxybenzophenone ne-Bba, Ukutholakala kwethu okuqhubekayo kwemikhiqizo yezinga eliphezulu nezisombululo kuhlanganiswe nesevisi yethu enhle kakhulu yokuthengisa ngaphambi kokuthengisa nangemva kokuthengisa kuqinisekisa ukuncintisana okuqinile emakethe eyandayo yomhlaba wonke.wamukelekile amakhasimende amasha namadala avela kuyo yonke imikhakha yempilo ukuze asithinte ukuze uthole ubudlelwano bebhizinisi besikhathi esizayo kanye nempumelelo efanayo!